Filing Details
- Accession Number:
- 0001415889-25-003065
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-02-04 20:30:21
- Reporting Period:
- 2025-01-31
- Filing Date:
- 2025-02-04
- Accepted Time:
- 2025-02-04 20:30:21
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1438533 | Travere Therapeutics Inc. | TVTX | Pharmaceutical Preparations (2834) | 262383102 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1763494 | M Eric Dube | C/O Travere Therapeutics, Inc. 3611 Valley Centre Dr., Suite 300 San Diego CA 92130 | Chief Executive Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-01-31 | 130,000 | $0.00 | 481,239 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2025-02-03 | 50,691 | $20.21 | 430,548 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee stock option (right to buy) | Acquisiton | 2025-01-31 | 260,000 | $0.00 | 260,000 | $20.46 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 260,000 | 2035-01-31 | No | 4 | A | Direct |
Footnotes
- Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
- This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
- The weighted average sale price for the transaction reported was $20.2076, and the range of prices were between $19.76 and $20.56. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.
Billionaire Hedge Funds
